Background: Pharmacokinetic/pharmacodynamic (PKPD) models developed based on data from in vitro timekill experiments have been suggested to contribute to more efficient drug development programmes and better dosing strategies for antibiotics. However, for satisfactory predictions such models would have to show good extrapolation properties.
Introduction
In vitro studies offer a unique possibility to study the relationship between drug exposure and antimicrobial efficacy. 1 With time-kill experiments, the growth and killing kinetics of a pathogen are followed over time and the observations are efficiently summarized and related to drug exposure in a pharmacokinetic/ pharmacodynamic (PKPD) model structure with parameters estimated based on available data. If it is found to adequately describe the underlying processes, the model may be used to predict drug efficacy in other settings than those experimentally tested, and thus can prove a useful tool, e.g. for translating experimental in vitro results into an in vivo situation. Such predictions require the model to show both good internal validation properties and extrapolation properties.
One way to improve extrapolation properties of a model is to incorporate prior knowledge of the studied system by using a mechanism-based modelling approach. 2, 3 For bacterial systems, it is well known that the antibacterial efficacy might be attenuated at high bacterial densities and this so-called inoculum effect has been described for a variety of drugs and bacteria in vitro as well as in vivo. 4, 5 However, the time-kill experiments are typically performed using a fixed starting inoculum size of $10 6 cfu/mL. In patients the bacterial density varies over time and the inoculum is often expected to be high when the treatment is introduced. If the PKPD model structure does not adequately describe the inoculum V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
effect, the efficacy of the treatment in the in vivo situation may be poorly predicted.
Of central importance for optimal antibiotic dosing is an understanding of the relationship between the selection of resistance and antibiotic drug exposure. Time-kill experiments can help to characterize this relationship. However, the number of different mutant strains is often large, and since time-kill experiments are time and labour consuming there is a restriction on the number of strains that can be studied. Ideally, a developed PKPD model should therefore allow prediction of the PD behaviour of related bacterial strains using only a limited amount of information (e.g. based on MIC determinations).
A mechanism-based PKPD model for Escherichia coli exposed to ciprofloxacin has previously been developed based on traditional time-kill experiments. 6 The mechanisms of ciprofloxacin resistance have been thoroughly studied 7 and a large number of isogenic derivatives, carrying up to five resistance mechanisms, have been constructed using E. coli K12 MG1655 as an ancestral strain. 8 The PKPD model development was based on E. coli K12 MG1655 and six of the mutants. 6 The model structure included growing and resting bacterial states to characterize the expected reduction in growth rate and antibacterial efficacy at high bacterial densities. 9 Model parameters were shared for the different strains, except for the parameter representing the drug potency (EC 50 ), which was estimated separately for each strain (full model). A high correlation (r 2 " 0.99) between the estimated EC 50 and the experimentally determined MIC was observed, and the EC 50 was thus expressed as a function of the MICs (EC 50 /MIC correlation model). Such a model might prove useful in predicting the potential for a dosing regimen to overcome resistance since the antibacterial potency against new strains may be based on only limited experimental data (in this case MICs).
The objective of this study was to externally evaluate, across experimental conditions, a previously described mechanismbased PKPD model developed according to the traditional set-up for in vitro time-kill experiments. This evaluation was performed by examining the extrapolation properties of the model using (i) higher bacterial start inocula and (ii) additional laboratory and clinical E. coli strains not studied during model development.
Materials and methods
This evaluation study was performed in a stepwise manner. First, model predictions were made according to an intended experimental protocol. Next, the experiments were carried out and model predictions were compared with observed bacterial counts. In the last step, the model structure and parameter estimates were re-evaluated based on the new data.
Bacterial strains and media
The susceptibility, genotype and fitness of the strains used in the study are described in Table 1 . For model development, E. coli MG1655 WT and six isogenic strains, carrying one to four mutations were used. 6, 8 To evaluate the predictive performance for higher start inocula, E. coli MG1655 and two of the mutant strains used in the model development (LM202 and LM378) were included. To evaluate the predictive performance across strains, seven additional strains, not included in the previous model development process, were used. Three of the strains originate from MG1655, carrying one to two mutations. E. coli Nu14, a clinical fluoroquinolone-susceptible cystitis isolate, was used as a standard clinical WT strain. 10 In addition, three clinical isolates (AB BIODISK Culture Collection, Solna, Sweden) originating from patients with uncomplicated urinary tract infections were included. These strains have been confirmed to carry mutations resulting in a 4-to 15-fold increase in MIC as compared with Nu14. 7 For time-kill experiments the bacteria were grown in Mueller-Hinton II (MHII) broth (BD BBL   TM ) and MHII agar plates were used for viable count measurements.
Antibiotic
Ciprofloxacin (Sigma Aldrich, 17850-5G-F) was dissolved in 0.1 M HCl to give stock solutions of 10 mg/mL and then further diluted using MHII broth to the desired concentrations. The stock solutions were stored at !4 C and used within 4 weeks. The MICs were determined using the macrodilution method in MHII broth. 6 
Time-kill experiments
The time-kill experiments were performed in accordance with our standard protocol. 6 To produce overnight cultures, single E. coli colonies were added to MHII broth and grown for 15-17 h. The overnight cultures were diluted 1:100 and grown for an additional 1.5 h to produce bacteria in logarithmic growth phase. Bacteria were added to the culture vessel to obtain a start inoculum of $10 6 cfu/mL. Ciprofloxacin was added to achieve a wide range of unbound drug concentrations, with the highest drug concentration studied resulting in an effect close to the maximum achievable effect (E max ). Samples for bacterial count measurements were taken prior to the addition of ciprofloxacin (0 h) and at 1, 2, 4, 10, 24 and 32 h during ciprofloxacin exposure. The sample was applied to one side of an agar plate and allowed to sink into the plate before spreading the bacteria. Potential drug carry-over was assessed by visually inspecting the distribution of colonies on the plate. If a clear zone was present, the plate was divided into two and the half where the sample was applied was ignored in the counting. Each experiment was carried out in at least duplicate at two different laboratories, with at least one growth control included each time an experiment was performed. The limit of detection (LOD) was 10 cfu/mL.
Evaluation of predictive performance using a high start inoculum
To obtain higher start inocula than 10 6 cfu/mL, bacteria from the overnight culture were diluted 1:100 in 50 mL prewarmed MHII broth in a baffled Erlenmeyer flask and grown for 2 h, resulting in bacteria in mid to late logarithmic growth phase. Bacteria were added to the culture vessel to obtain start inocula in the range of 10 6 -10 8 cfu/mL. To produce start inocula in the late stationary phase, the inocula were prepared according to the standard procedure described above to reach 10 6 cfu/mL. The bacteria were thereafter allowed to grow in the culture vessel for 16 h before ciprofloxacin was added and the time-kill experiments were started. Ciprofloxacin was added to obtain concentrations corresponding to 0.5, 2 and 8 % MIC for experiments with bacteria in the logarithmic growth phase and 2, 8 and 16 % MIC for bacteria in the stationary phase.
Evaluation of predictive performance across E. coli strains Start inocula of 10 6 cfu/mL were prepared according to the standard procedure. Ciprofloxacin was added to obtain concentrations of 0, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4 and 8 % MIC. For the clinical strains a fraction of the bacteria was found to be able to resist the antibiotic exposure. To characterize the growth and the antibiotic-induced killing of such persisting bacteria an additional set of time-kill experiments was performed using ciprofloxacin concentrations of 0, 1 and 2 % MIC. During these experiments a sample was taken from the culture vessel at 10 h and used to produce a new External PKPD model evaluation JAC overnight culture. Based on this overnight culture the time-kill experiments were repeated.
PKPD model
The evaluated PKPD model (illustrated in Figure 1 ) has been described in detail elsewhere. 6 The bacteria were assumed to belong either to a susceptible sub-population (1) or to a less susceptible (pre-existing resistant) sub-population (2) . For each of these two sub-populations the bacteria can exist in three different states: (i) a growing drug-susceptible state (S 1 and S 2 ); (ii) a resting (non-growing) and non-susceptible state (R 1 and R 2 ); or (iii) a non-colony-forming state (Nc 1 and Nc 2 ).
Model evaluation
Initially, the original model structure ( Figure 1 ) and parameter estimates (Table 2 ) were used to predict the observations in the new experiments based on the planned experimental design (intended start inoculum, ciprofloxacin concentrations and sampling timepoints). In this step no reevaluation of parameter estimates based on the new data was performed. For experiments with the start inoculum in the late stationary phase, the previously developed model was used to simulate the fraction of bacteria in the different states at the time of antibiotic addition, and compartments were initialized accordingly. For all other experiments, the bacteria were assumed to be in the susceptible state at the start of the experiment (the same assumption as used during model development). During model development, no statistical improvement in the model fit to the data was observed when allowing the growth rate to be strain specific. Thus, in all predictions the growth rate for all strains was assumed to be the same as for the wildtype. The strains used when evaluating the predictive performance for higher bacterial densities were included during the model development process, and the estimates for the model with separate estimation of the EC 50 for each strain (full model) were used in the predictions. For the evaluation across strains, the parameters of the EC 50 /MIC correlation model previously described by Khan et al. 6 were used. In the original (full) model separate EC 50 values were estimated for each of the seven strains investigated. A strong correlation was observed between the EC 50 estimates and the experimentally observed MICs. As an alternative, the model was reparameterized where the EC 50 was derived based on the experimentally observed MIC, resulting in equation (1).
In a second step, the model parameters were re-estimated and, if judged necessary, alternative model structures were evaluated based on all available data.
Additive residual error models on log-transformed data were used. The bacterial counts were here assessed using replicate plating. The level 2 (L2) data item was used to group together samples taken at the same timepoint. This approach allows for estimation of a replicate-specific residual error as well as a common residual error to account for correlated residual errors resulting from the replicate plating. 9 For timepoints where all plated samples were below the LOD the M3 method was used, which maximizes the likelihood for the observation at that timepoint being below the LOD. 11, 12 For the start inoculum, the variability was handled using the B2 method, where the observed bacterial count at the start of the experiment was treated as a covariate associated with a residual error of the same magnitude as other observations. 13 The difference in the NONMEM supplied objective function value (OFV) was used to rank models. To discriminate between nested models, the likelihood ratio test was used to evaluate statistical significance, where a reduction of at least 3.84 for one degree of freedom was regarded as statistically significant (P , 0.05). Because of the heterogeneity in study design, normalized prediction distribution errors (NPDE), 14 computed by NONMEM, were selected as the method of choice for model diagnostics. Figure 1 . Schematic illustration of the PKPD model characterizing ciprofloxacin-induced killing of E. coli. 6 The total bacterial population is divided into two subpopulations, an original main population (1) and a pre-existing resistant population (2) . C represents the drug concentration, S represents drug-susceptible, growing bacteria, R represents non-susceptible, non-growing bacteria, and Nc represents drug-susceptible, non-growing, non-colony-forming bacteria. k growth is the growth rate constant, k death is the natural death rate constant, k SR is the transfer rate constants between S and R, k SNc and k NcS and are transfer rate constants between S and Nc, and k drug describes the drug effect on bacterial killing. The transfer from S to R was assumed to be bacterial density dependent according to a linear function with a proportionality constant (PC) times the total bacterial content in the system (B TOT ). The susceptible subpopulation (1) and less susceptible subpopulation (2) shared all parameters except k growth and EC 50 . The fraction of bacteria belonging to the less susceptible subpopulation (2) at the start of the experiment was estimated as a parameter (S 2start ). Table 2 . PKPD model parameters for the full and EC 50 /MIC correlation model as estimated earlier 6 and here used for predictions, for the EC 50 /MIC correlation model with re-estimated parameters (relative standard errors, RSE) and for the further developed model with the intermediate bacterial state. In the re-estimation the dataset used earlier and the new data from this study were combined and the clinical strains were allowed to have a fraction of the bacteria in the resting state (R) at the start of the experiment (previously assumed to be 0) 
Results
Evaluation of predictive performance using a high start inoculum
Experimental data
In total, 177 new time-kill experiments were performed for E. coli MG1655 WT, mutant LM202 and mutant LM378, with start inocula in the range of 10 5 -10 9 cfu/mL ( Figure 2 ). The majority of the experiments (n " 132) were performed using bacteria in the exponential growth phase (Figure 2 , panels 1-4), while others (n " 45) represent starting inocula in the late stationary phase (Figure 2, panel 5) . A decrease in the rate and extent of bacterial killing was observed when the start inoculum was increased for all three strains investigated. When using the standard inoculum of 10 6 cfu/mL an exposure to 2 % MIC of ciprofloxacin resulted in rapid bacterial killing with bacterial counts below LOD from 10 h and onwards in the majority of the experiments, thus representing a reduction in cfu/mL of !5 log 10 . In contrast, when the start inoculum was increased 100-fold the same drug exposure resulted in a reduction in bacterial count of 2 log 10 .
PKPD model prediction
For the majority of the experiments the drug effect was well predicted by the previously developed PKPD model, even when using higher start inocula (Figure 2 ). For the experiments with bacteria in the late stationary phase the model underestimated the initial bacterial killing rate (Figure 2, panel 5 ).
Evaluation of predictive performance across E. coli strains Experimental data
A total of 126 time-kill experiments were performed using seven E. coli strains not included during model development (Figure 3 ). For the three strains originating from MG1655 (LM351, LM421 and LM862) a ciprofloxacin concentration !2 % MIC resulted in a rapid and pronounced killing effect with bacterial counts ,LOD within the first hours of the experiment. For the four clinical strains (Nu14, C128, C47 and C77) a clear biphasic killing effect was observed. A moderate initial drop in cfu/mL of $3 log 10 was followed by a second phase with a slow decline in bacterial counts with bacterial count .LOD at the end of the experiment. To explore the characteristics of these 'persisting' bacteria, a new set of experiments was performed where pre-exposed bacteria were rechallenged and followed over 24 h. After reculturing, the persisting bacteria were as susceptible to ciprofloxacin as the original bacteria, indicating that the bacteria were in a reversible state (data not shown).
PKPD model prediction
The EC 50 /MIC correlation model was also able to accurately predict the bacterial killing effect for the three previously untested laboratory strains based on the observed MICs (Figure 3, top) . For the clinical strains, the model overpredicted the initial killing effect following high ciprofloxacin exposures and did not describe the biphasic killing behaviour experimentally observed.
Model re-evaluation
The parameters of the original model structure were re-estimated based on all available data ( Table 2 ). To describe the high level of persistent bacteria for the clinical strains, a fraction of the bacteria (3.9%10 3 cfu/mL per 10 6 starting cfu/mL) was estimated to be in the resting state at the start of the experiment for those strains (OFV drop of 55). To better characterize the shape of the ciprofloxacin-induced killing in the stationary phase, different model structures were evaluated. In the best of the tested models, bacteria in R (R1 and R2) were allowed to transfer (with an estimated first-order rate constant, k RR ) to an additional compartment representing non-susceptible, non-growing bacteria without a natural death rate. In this model, bacteria in R1 and R2 were assumed to be in an intermediate bacterial state, and affected by the drug, with EC 50 s scaled with an estimated scaling factor (SF EC50 ) based on the EC 50 estimates for S1 and S2. This model structure provided a better description of the stationary phase data with an overall drop in OFV of 72 units ( 
Discussion
This study shows that a mechanism-based PKPD model structure developed using data from traditional start inoculum experiments could describe the inoculum effect in time-kill experiments without any parameter re-estimation. Furthermore, the model was able to predict bacterial growth and killing over time for additional laboratory and clinical strains not used during model development, with the potency (EC 50 ) derived from observed MICs. This ability to predict new experimental conditions based on only a limited amount of new information highlights the potential of combining structured, longitudinal preclinical experiments with mechanism-based mathematical modelling to learn about drugbacteria interactions and the bridge between preclinical and clinical conditions, and to make informed decisions for improved antimicrobial therapy.
The presence of an inoculum effect is a well-known phenomenon. In agreement with previous studies, 4, 19 the antibiotic drug efficacy in this study remained fairly constant for bacterial densities ,10 7 cfu/mL, both for observed data and model predictions (Figure 2) . At higher densities the killing effect was considerably attenuated. Several underlying mechanisms have been suggested to explain this phenomenon. One hypothesis is that there is a reduction in the number of drug molecules per number of bacteria. 4, 20 The number of drug molecules per bacterium is high also at high bacterial densities; however, the number of molecules bound to live or dead bacteria and the number of molecules needed to kill bacteria are largely unknown. High bacterial densities have also been associated with a change in the physiological state of the bacteria, with the bacteria entering a non-growing state with reduced drug susceptibility. This has been suggested to result from a decrease in nutrition or environmental changes in the culture. However, the growth characteristics (the apparent Nielsen et al. External PKPD model evaluation JAC growth rate and bacterial count in the stationary phase) have been found to be similar between static and dynamic experimental systems, where the environment in the latter system is continuously refreshed, which implies that the entry into the stationary phase is due primarily to reasons other than a lack of nutrition or accumulation of waste products.
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A logistic growth model is often applied to describe the observed reduction in growth rate at high inocula. 22, 23 According to this model, the bacteria present at high densities are assumed to be as susceptible to the antibiotic effect as cells in the exponential growth phase. Hence such models would be expected to overpredict the killing at high inocula. One approach to account for the inoculum effect has been to introduce a function where the effective antibiotic concentration decreases with increasing start inoculum. 4, 24 Here the inoculum effect is assumed to be static and determined based on the initial bacterial density only. Therefore, this implementation lacks the ability to accurately describe the change in drug efficacy when the bacterial density varies over time. A more mechanism-based approach has been suggested by Bulitta et al., 25, 26 in which all viable bacteria are assumed to synthesize hypothetical signal molecules. These molecules can then be introduced to affect drug efficacy-related parameters as well as the growth rate. 25, 26 With increased knowledge regarding the mechanisms involved, allowing mediators of the cell-to-cell communication to be quantifiable, such data may improve the predictive ability of the model.
In contrast to the examples described above, no data from experiments with high bacterial densities were available during the model-building process performed by Khan et al. 6 Nevertheless, the knowledge that normally growing drug-susceptible cells might transform into resting, non-growing and non-susceptible cells at late exponential growth phase 19, 27 was incorporated into the original model structure. Given the lack of information, a parsimonious model was applied, where a simple one-parameter linear function was used for the transfer rate constant (k SR " PC % B TOT ) between the two states. 9 Despite its simplistic nature, this model structure was found to characterize reasonably well experiments with higher inocula in the mid to late exponential growth phase, even without parameter re-estimation. To better describe the data, including the stationary-phase experiments, we evaluated a model structure similar to the one described by Ungphakorn et al. 28 This model includes an intermediate bacterial state between the growing drug-susceptible state (S) and the resting non-susceptible state (R). In the intermediate state the bacteria do not grow but are still drug susceptible, albeit to a lower degree than the susceptible bacteria. The R state was assumed to have no natural death rate. This model was able to provide a significantly improved fit for the stationary-phase data. However, this came at the cost of a more complex model structure, requiring the availability of stationary-phase start-inoculum data to support parameter estimation. Further, to describe stationary-phase experiments may not be of highest interest, and for other data, including high-start-inoculum data, the original model structure was deemed sufficient.
The quantified EC 50 /MIC correlation model was found to accurately predict ciprofloxacin activity against new isogenic strains based only on previous parameter estimates and the observed MIC. A relationship between EC 50 and MIC has been discussed previously, 29, 30 and shown experimentally using in vitro data, 31 with application to in vivo efficacy data showing good translational properties. 32 Interestingly, all clinical strains investigated had a clear biphasic killing behaviour and a higher than expected level of drug-tolerant persistent bacteria. Persisters have been described as metabolically dormant (non-proliferating) bacteria with a high tolerance to antibiotics. Unlike resistant bacteria, persisters do not grow in the presence of antibiotics, and since they are thought to be genetically identical to the main population, they are described as phenotypically drug tolerant. 27, 33 This phenomenon was described as long ago as the 1940s and has since then been demonstrated for a large number of antimicrobial agents and bacterial species. By maintaining an inoculum in the early growth phase (e.g. by repeated reinoculation), persister cells are diluted, indicating that persisters are formed mainly in the late exponential growth phase. 19, 33 Further, when transferring bacteria from a stationary phase into fresh media, the majority of the bacteria resume normal growth. These characteristics of persistent bacteria are in line with the model implementation used here, where growing bacteria become non-growing, and less or non-susceptible to ciprofloxacin at high bacterial densities with clinical strains showing an increased fraction of persistent bacteria.
Limitations of the study include the limited time-frame (32 h), the use of static drug exposures and the investigation of only one drug/bacteria combination. However, the structure of the model has previously been found to be predictive of a wide range of antibiotic-bacteria combinations, including drugs with different mechanisms of action, PKPD relationships and mechanisms of resistance, when tested individually as well as in combination treatments. 9, 21, 34, 35 The model structure has also been shown to accurately describe the time-course of drug efficacy following dynamic ciprofloxacin concentrations, 36 and to successfully replicate in vivo data. [37] [38] [39] When linked to human PK models, such PKPD models have also been used to predict bacterial killing in different clinical settings. For example, a model describing the bacterial killing and adaptive resistance of E. coli exposed to gentamicin was linked to the PK profile in pre-term and term newborn infants and used to compare expected efficacy following different dosing regimens. 21 Recently, the PKPD model evaluated here was linked to a whole-body physiologically based PK (WB-PBPK) model to illustrate the potential to predict the time-course of bacterial killing at different sites of infection. 40 However, the translational properties of the models need further investigation, and any extrapolation beyond the timeframe studied should be done with caution.
In conclusion, a mechanism-based PKPD model developed based on standard inoculum time-kill data was shown to adequately predict the decreased antibacterial killing effect due to the inoculum effect. The model also adequately predicted efficacy across isogenic E. coli strains using only the MIC as additional input. For the clinical strains a higher level of persistent cells was observed, which was well characterized by re-estimation of the number of persistent cells in the start inoculum. Mechanism-based PKPD modelling developed from well-designed early preclinical time-kill experiments has great potential to facilitate streamlined drug development programmes and to serve as a decision-making tool, e.g. in the selection of dosing regimens in the presence of different degrees of resistance.
